FDA rejects Summit, Akeso's ivonescimab in narrow lung cancer setting
The FDA rejected a new cancer treatment from Summit Therapeutics and Akeso in a decision that analysts largely expected, but ultimately shouldn’t dim the prospects for a promising class of drugs. Regulators turned down ivonescimab ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.